How a decade-old pharma deal could cost Cinven’s CEO his job
Cinven’s CEO Supraj Rajagopalan faces potential disqualification from running UK companies over a pharmaceutical pricing scandal. The same deal that propelled him to leadership in 2015 now threatens to end his career. Regulators found Advanz Pharma gouged the NHS with excessive drug prices during Ci